The effect of evidence-based medication use on long-term survival in patients hospitalised for heart failure in Western Australia

Medical Journal of Australia

Volumn 192, Issue 6, 2010, Pages 306-310

  Teng, Tiew Hwa Katherine ^a   Hung, Joseph ^b   Finn, Judith ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE;

AGED; ARTICLE; AUSTRALIA; CLINICAL TRIAL; COHORT ANALYSIS; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; FEMALE; GROUPS BY AGE; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; MULTICENTER STUDY; PREDICTOR VARIABLE; PRESCRIPTION; RETROSPECTIVE STUDY; SURVIVAL TIME; TERTIARY HEALTH CARE; TREATMENT INDICATION; TREND STUDY;

EID: 77952326793     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03528.x     Document Type: Article

References (25)

1. Krum H, Jelinek MV, Stewart S, et al. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust 2006; 185: 549-557.
2. Clark RA, McLennan S, Dawson A, et al. Uncovering a hidden epidemic: a study of the current burden of heart failure in Australia. Heart Lung Circ 2004; 13: 266-273. (Pubitemid 39317649)
3. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Circulation 2001; 104: 2996-3007.
4. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456.
5. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian metaanalysis. Ann Intern Med 2001; 134: 550-560. (Pubitemid 32245316)
6. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675. (Pubitemid 33126822)
7. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
8. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336: 525-533.
9. Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007; 153: 1021-1028.
10. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002; 360: 1631-1639.
11. Krum H, Tonkin AM, Currie R, et al. Chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) Study. Med J Aust 2001; 174: 439-444. (Pubitemid 32466066)
12. Lowe JM, Candlish PM, Henry DA, et al. Management and outcomes of congestive heart failure: a prospective study of hospitalised patients. Med J Aust 1998; 168: 115-118. (Pubitemid 28055076)
13. Wlodarczyk JH, Keogh A, Smith K, McCosker C. CHART: congestive cardiac failure in hospitals, an Australian review of treatment. Heart Lung Circ 2003; 12: 94-102. (Pubitemid 37265886)
14. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-2736.
15. Fonarow GC, Gheorghiade M, Abraham WT. Importance of in-hospital initiation of evidence-based medical therapies for heart failure - a review. Am J Cardiol 2004; 94: 1155-1160. (Pubitemid 39424219)
16. Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999; 23: 453-459.
17. Teng T-H, Finn J, Hung J, et al. A validation study: how effective is the hospital morbidity data as a surveillance tool for heart failure in Western Australia? Aust N Z J Public Health 2008; 32: 405-407.
18. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA 1999; 281: 1714-1717.
19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
20. Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med 2001; 161: 2223-2228.
21. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007; 116: 737-744.
22. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43: 317-327. (Pubitemid 38167688)
23. Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53: 184-192.
24. Kotlyar E, Keogh AM, Macdonald PS, et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21: 1290-1295. (Pubitemid 35477743)
25. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.